1st Quarter - Report
ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC) for AMGEN
Client
Income
$60,000
Expenses
—
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Issues related to biosimilars, generally Issues related to drug pricing and value, generally Issues related to the importation of prescription medicines Issues involving the Federal, Food, Drug and Cosmetic Act (FFDCA), generally
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEVEN E IRIZARRY | — |
| VINCENT A. ROBERTI, SR. | — |
Medicare/Medicaid MMM
Medicare Part B coverage and reimbursement issues Issues related to Medicare Part D Coding and reimbursement for oncology drugs/biologics/biosimilars Issues relating to the 340B Drug Pricing Program
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEVEN E IRIZARRY | — |
| VINCENT A. ROBERTI, SR. | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.